PURPOSE: High-dose intravenous glucocorticoids are the standard first-line treatment in active, moderate to severe and severe thyroid eye disease (TED). We evaluate the usefulness of clinical activity score (CAS) and thyroid-stimulating immunoglobulin (TSI) as predictors and/or post-treatment markers of corticoresistance in patients with TED and the effect of rituximab in second-line treatment. METHODS: We enrolled 236 patients with an active TED into this retrospective single-tertiary-center cohort study. All patients were initially treated with high-dose systemic glucocorticoids. Rituximab was later administered to 29 of 42 corticoresistant patients. RESULTS: The CAS of the corticoresistant patients was significantly higher both before (p = 0.0001) and after (p = <0.0001) first-line treatment compared to the corticosensitive group. ROC analysis established the cut-point value as CAS ≥ 2.5 with a sensitivity of 96.3%, specificity of 57.5% and area under the curve of 82.8%. In 22 patients treated with rituximab, CAS gradually decreased to zero values without reactivation during extended follow-up. There was no difference in the TSI of corticosensitive and corticoresistant patients before or after first-line therapy. CONCLUSION: CAS ≥ 2, after first-line treatment, could be used as a corticoresistance marker. Corticoresistant patients should be subject to long-term follow-up for early detection of reactivation to reduce the delay to second-line treatment. Rituximab is a well-tolerated choice of second-line treatment and has a long-lasting effect on disease activity. Although TSI is a valuable biomarker of Graves' disease and TED activity, according to our results, TSI cannot be used as a marker of corticoresistance.

Department of Computer Science Faculty of Electrical Engineering and Computer Science VSB Technical University of Ostrava Ostrava Czech Republic

Department of Internal Medicine 3 Nephrology Rheumatology and Endocrinology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Olomouc Czech Republic

Department of Ophthalmology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Olomouc Czech Republic

See more in PubMed

G. Kahaly, F. Petrak, J. Hardt, S. Pitz, U. Egle psychosocial morbidity of Graves’ orbitopathy. Clin. Endocrinol. (2005). 10.1111/j.1365-2265.2005.02352.x PubMed

C. Terwee, F. Dekker, M. Mourits, et al. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin. Endocrinol. (2001). 10.1046/j.1365-2265.2001.01241.x PubMed

C. McAlinden. An overview of thyroid eye disease. Eye Vision (2014). 10.1186/s40662-014-0009-8 PubMed PMC

P. Perros, L. Hegedüs, L. Bartalena, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J. Rare Dis. (2017). 10.1186/s13023-017-0625-1 PubMed PMC

M. Mourits, M. Prummel, W. Wiersinga, L. Koornneef. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol. (1997). 10.1046/j.1365-2265.1997.2331047.x PubMed

L. Bartalena, G. Kahaly, L. Baldeschi, et al.: The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur. J. Endocrinol. (2021). 10.1530/EJE-21-0479 PubMed

L. Bartalena, L. Baldeschi, A. Dickinson, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid (2008). 10.1089/thy.2007.0315 PubMed

G. Kahaly, T. Diana. TSH receptor antibody functionality and nomenclature. Front. Endocrinol (2017). 10.3389/fendo.2017.00028 PubMed PMC

T.J. Smith, L. Hegedüs. Graves’ disease. N. Engl. J. Med. (2016). 10.1056/NEJMra1510030

G. Kahaly, M. Riedl, J. König et al: Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. (2018). 10.1016/S2213-8587(18)30020-2 PubMed

Rajabi, M.T., Rafizadeh, S.M., Mohammadi, A., et al: Mycophenolate mofetil (CellCept®) in combination with low dose prednisolone in moderate to severe Graves’ orbitopathy. Front. Med. (2022). 10.3389/fmed.2022.788228 PubMed PMC

S. Zang, K.A. Ponto, G.J. Kahaly. Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J. Clin. Endocrinol. Metab. (2011). 10.1210/jc.2010-1962. PubMed

J. Supronik, M. Szelachowska, A. Kretowski, K. Siewko. Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives. Endocrine Connections (2022). 10.1530/EC-22-0303 PubMed PMC

G. Vannucchi, I. Campi, D. Covelli et al. Effect of a very low dose of Rituximab on active moderate-severe Graves’ orbitopathy: an interim report. Endocrine Abstracts (2015). 10.1530/endoabs.37.GP.27.05

M Salvi Small dose of rituximab for graves orbitopathy: New insights into the mechanism of action. Arch. Ophthalmol. (2012). 10.1001/archopthalmol.2011.1215 PubMed

M. Stan, M Salvi. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves’ orbitopathy – lessons from randomized control trials. Eur. J. Endocrinol. (2017). 10.1530/EJE-16-0552 PubMed

I. Campi, G. Vannucchi, I. Muller et al. Therapy with different dose regimens of rituximab in patients with active moderate-to-severe graves’ orbitopathy. Front. Endocrinol. (2022). 10.3389/fendo.2021.790246 PubMed PMC

M. Salvi, G. Vannucchi, N. Currò et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: A randomized controlled study. J. Clin. Endocrinol. Metab. (2015). 10.1210/jc.2014-3014 PubMed PMC

D. Karasek, L. Cibickova, M. Karhanova, J. Kalitova, J. Schovanek, Z. Frysak. Clinical and immunological changes in patients with active moderate-to-severe Graves̕ orbitopathy treated with very low-dose Rituximab. Endokrynologia Polska (2017). 10.5603/EP.a2017.0040 PubMed

H. Burch, P. Perros, T. Bednarczuk et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur. Thyroid J. (2022). 10.1530/ETJ-22-0189 PubMed PMC

M. Moleti, M.A. Violi, D. Montanini, C. Trombetta, et al. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves’ orbitopathy (GO): A prospective, randomized, single-blind clinical trial. J. Clin. Endocrinol. Metab. (2014). 10.1210/jc.2013-3093 PubMed

J. Perez-Moreiras, J. Gomez-Reino, J. Maneiro, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial. Am. J. Ophthalmol. (2018). 10.1016/j.ajo.2018.07.038 PubMed

M. Prummel, A. Berghout, W. Wiersinga, M. Mourits, L. Koornneef, L. Blank. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. The Lancet (1993). 10.1016/0140-6736(93)92001-A PubMed

M. Prummel, M. Mourits, A. Berghout, E. Krenning, R. van der Gaag, L. Koornneef, W. Wiersinga. Prednisone and cyclosporine in the treatment of severe graves’ ophthalmopathy. N. Engl. J. Med. (1989). 10.1056/NEJM198911163212002 PubMed

T. Diana, K. Ponto, G. Kahaly. Thyrotropin receptor antibodies and Graves’ orbitopathy. J. Endocrinol. Investig. (2021). 10.1007/s40618-020-01380-9 PubMed PMC

A. George, T. Diana, J. Längericht, G. Kahaly. Stimulatory thyrotropin receptor antibodies are a biomarker for Graves’ orbitopathy. Front. Endocrinol. (2021). 10.3389/fendo.2020.629925 PubMed PMC

K. Ponto, M. Kanitz, P. Olivo, S. Pitz, N. Pfeiffer, G. Kahaly Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology, 118 (11), 2279-2285 (2011) PubMed

A. Erdei, G. Paragh, P. Kovacs, et al: Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: A five-year follow-up study. Autoimmunity (2014). 10.3109/08916934.2014.939266 PubMed

L. Du Pasquier-Fediaevsky, S. Andrei, M. Berche, L. Leenhardt, E. Héron, S. Rivière. Low-dose rituximab for active moderate to severe Graves’ orbitopathy resistant to conventional treatment. Ocular Immunol. Inflamm. (2019). 10.1080/09273948.2018.1453078 PubMed

M. Lucarelli, J. Shore. Management of thyroid optic neuropathy. Int. Ophthalmol. Clinics (1996). 10.1097/00004397-199603610-00018 PubMed

F. Rundle, C. Wilson, Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin. Sci. 5(3-4), 177–194 (1945) PubMed